Indications
Lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies.
Composition
- Active substance
- mosunetuzumab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Lunsumio
- Active substance
- mosunetuzumab
- ATC code
- L01FX25
- Therapeutic area
- Lymphoma, Follicular
- Marketing authorisation holder
- Roche Registration GmbH
- Status
- Authorised